David Westenberg
Stock Analyst at Piper Sandler
(3.66)
# 741
Out of 4,784 analysts
162
Total ratings
45.36%
Success rate
7.74%
Average return
Main Sectors:
Stocks Rated by David Westenberg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELAN Elanco Animal Health | Maintains: Neutral | $16 → $12 | $10.81 | +11.01% | 9 | Mar 6, 2025 | |
| TEM Tempus AI | Maintains: Neutral | $70 → $55 | $51.97 | +5.83% | 3 | Mar 4, 2025 | |
| NTRA Natera | Maintains: Overweight | $200 → $205 | $148.30 | +38.23% | 14 | Mar 4, 2025 | |
| FLGT Fulgent Genetics | Maintains: Neutral | $22 → $16 | $16.85 | -5.04% | 7 | Mar 4, 2025 | |
| CTKB Cytek Biosciences | Maintains: Overweight | $8.5 → $8 | $4.10 | +95.12% | 9 | Mar 4, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $200 → $205 | $165.02 | +24.23% | 13 | Feb 27, 2025 | |
| NEO NeoGenomics | Maintains: Overweight | $21 → $18 | $9.48 | +89.87% | 8 | Feb 26, 2025 | |
| GH Guardant Health | Maintains: Overweight | $34 → $50 | $45.15 | +10.74% | 8 | Feb 26, 2025 | |
| EXAS Exact Sciences | Maintains: Overweight | $75 → $70 | $44.99 | +55.59% | 10 | Feb 26, 2025 | |
| PACB Pacific Biosciences of California | Reiterates: Neutral | $2.5 → $2 | $1.24 | +61.29% | 7 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 → $11 | $8.22 | +33.82% | 12 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $260 | $231.67 | +12.23% | 3 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $185 → $190 | $82.28 | +130.92% | 15 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $435 → $510 | $422.54 | +20.70% | 10 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $165 → $180 | $166.00 | +8.43% | 6 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $17 → $13 | $8.96 | +45.09% | 10 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 → $3 | $1.49 | +101.34% | 7 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $3 | $3.22 | -6.83% | 7 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $9.41 | - | 1 | Mar 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $35.87 | - | 2 | Jan 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $38.23 | - | 1 | Nov 21, 2017 |
Elanco Animal Health
Mar 6, 2025
Maintains: Neutral
Price Target: $16 → $12
Current: $10.81
Upside: +11.01%
Tempus AI
Mar 4, 2025
Maintains: Neutral
Price Target: $70 → $55
Current: $51.97
Upside: +5.83%
Natera
Mar 4, 2025
Maintains: Overweight
Price Target: $200 → $205
Current: $148.30
Upside: +38.23%
Fulgent Genetics
Mar 4, 2025
Maintains: Neutral
Price Target: $22 → $16
Current: $16.85
Upside: -5.04%
Cytek Biosciences
Mar 4, 2025
Maintains: Overweight
Price Target: $8.5 → $8
Current: $4.10
Upside: +95.12%
Zoetis
Feb 27, 2025
Maintains: Overweight
Price Target: $200 → $205
Current: $165.02
Upside: +24.23%
NeoGenomics
Feb 26, 2025
Maintains: Overweight
Price Target: $21 → $18
Current: $9.48
Upside: +89.87%
Guardant Health
Feb 26, 2025
Maintains: Overweight
Price Target: $34 → $50
Current: $45.15
Upside: +10.74%
Exact Sciences
Feb 26, 2025
Maintains: Overweight
Price Target: $75 → $70
Current: $44.99
Upside: +55.59%
Pacific Biosciences of California
Feb 20, 2025
Reiterates: Neutral
Price Target: $2.5 → $2
Current: $1.24
Upside: +61.29%
Feb 20, 2025
Reiterates: Overweight
Price Target: $7 → $11
Current: $8.22
Upside: +33.82%
Feb 10, 2025
Maintains: Neutral
Price Target: $240 → $260
Current: $231.67
Upside: +12.23%
Feb 10, 2025
Maintains: Overweight
Price Target: $185 → $190
Current: $82.28
Upside: +130.92%
Feb 10, 2025
Maintains: Neutral
Price Target: $435 → $510
Current: $422.54
Upside: +20.70%
Feb 3, 2025
Reiterates: Neutral
Price Target: $165 → $180
Current: $166.00
Upside: +8.43%
Jan 21, 2025
Reiterates: Neutral
Price Target: $17 → $13
Current: $8.96
Upside: +45.09%
Nov 19, 2024
Reiterates: Overweight
Price Target: $4 → $3
Current: $1.49
Upside: +101.34%
Nov 13, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $3.22
Upside: -6.83%
Mar 5, 2020
Initiates: Buy
Price Target: n/a
Current: $9.41
Upside: -
Jan 4, 2018
Upgrades: Buy
Price Target: n/a
Current: $35.87
Upside: -
Nov 21, 2017
Initiates: Neutral
Price Target: n/a
Current: $38.23
Upside: -